行情

LXRX

LXRX

莱斯康制药
NASDAQ

实时行情|Nasdaq Last Sale

3.630
+0.100
+2.83%
交易中 14:34 11/19 EST
开盘
3.500
昨收
3.530
最高
3.690
最低
3.460
成交量
75.51万
成交额
--
52周最高
8.70
52周最低
1.125
市值
3.86亿
市盈率(TTM)
2.664
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

LXRX 新闻

  • Edited Transcript of LXRX earnings conference call or presentation 7-Nov-19 1:00pm GMT
  • Thomson Reuters StreetEvents.3天前
  • Lexicon Pharmaceuticals to Present at Upcoming Investor Conference
  • GlobeNewswire.4天前
  • Are Investors Undervaluing Lexicon Pharmaceuticals (LXRX) Right Now?
  • Zacks.5天前
  • UPDATE 1-FDA panel votes against Lilly-Boehringer Ingelheim's diabetes drug
  • Reuters.5天前

更多

所属板块

生物技术和医学研究
+2.23%
制药与医学研究
+0.77%

热门股票

名称
价格
涨跌幅

LXRX 简况

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development. XERMELO is an orally-delivered small molecule compound approved by the Food and Drug Administration (FDA) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. It is developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound that it is developing for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound that the Company is developing for the treatment of neuropathic pain.
展开

Webull提供Lexicon Pharmaceuticals, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。